BLLN BillionToOne, Inc. - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
BLLN Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Diagnostics & Research
Current Price
Live
$87.57
Analyst Target
$135.29
+54.5%
Upside
52W High
$138.7
52W Low
$80.0
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
65%
Analysis Accuracy
BLLN exhibits a weak Piotroski F-Score of 4/9, indicating marginal financial health, while the absence of an Altman Z-Score prevents a full solvency assessment. Despite strong revenue growth of 117.4% YoY and solid gross margins, profitability remains negative overall with a -4.36% net margin. Valuation metrics are stretched, with a Forward P/E of 230.45 and Price/Sales of 15.77, though analyst consensus supports a 'buy' recommendation with a $135.29 target price. Recent price performance has been weak over the past year (-19.6%), but insider sentiment is neutral and liquidity ratios are exceptionally strong.
Key Strengths
Exceptional revenue growth of 117.4% YoY, significantly above sector average of 61.94%
Strong gross margin of 65.15%, indicating pricing power and efficient cost control
Exceptional liquidity with a current ratio of 6.17 and quick ratio of 5.63
Low debt/equity ratio of 0.60, well below sector average of 2.69
Analyst consensus is 'buy' with a substantial upside target of $135.29 vs current $87.57
Key Risks
Piotroski F-Score of 4/9 suggests weak to stable financial health, raising concerns about earnings quality and stability
Negative net profit margin of -4.36% despite positive operating margin, indicating high non-operating expenses or tax inefficiencies
Extremely high Forward P/E of 230.45, implying very high growth expectations that may not be sustainable
Price/Sales of 15.77 is elevated relative to peers and historical norms, increasing vulnerability to multiple contraction
Lack of key financial data (ROE, ROA, ROIC, cash flow, shares outstanding) limits full financial health assessment
AI Fair Value Estimate
Based on comprehensive analysis
$115.0
+31.3% above current price
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare BLLN against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning BLLN from our newsroom.
Newest → oldest
No matching news yet.